Summit Creek Advisors LLC Sells 36,929 Shares of Vericel Co. (NASDAQ:VCEL)

Summit Creek Advisors LLC trimmed its stake in Vericel Co. (NASDAQ:VCEL - Free Report) by 7.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 440,748 shares of the biotechnology company's stock after selling 36,929 shares during the quarter. Vericel comprises about 2.1% of Summit Creek Advisors LLC's holdings, making the stock its 22nd biggest position. Summit Creek Advisors LLC owned 0.92% of Vericel worth $15,695,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of VCEL. DekaBank Deutsche Girozentrale bought a new stake in Vericel during the 4th quarter valued at $33,000. GAMMA Investing LLC bought a new stake in shares of Vericel during the fourth quarter worth about $65,000. Sentry Investment Management LLC acquired a new stake in shares of Vericel in the 4th quarter worth about $136,000. PNC Financial Services Group Inc. lifted its position in Vericel by 8.1% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,582 shares of the biotechnology company's stock valued at $154,000 after acquiring an additional 344 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Vericel during the 4th quarter valued at about $197,000.

Analyst Ratings Changes

A number of research firms have recently weighed in on VCEL. TheStreet upgraded Vericel from a "d+" rating to a "c-" rating in a report on Monday, January 29th. StockNews.com cut Vericel from a "hold" rating to a "sell" rating in a research note on Friday. Truist Financial reiterated a "buy" rating and issued a $54.00 target price on shares of Vericel in a research note on Tuesday, March 26th. Finally, HC Wainwright boosted their price target on shares of Vericel from $53.00 to $55.00 and gave the stock a "buy" rating in a report on Thursday. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Vericel presently has a consensus rating of "Moderate Buy" and an average price target of $46.80.

Vericel Stock Performance

VCEL traded up $0.42 during midday trading on Monday, reaching $48.52. The company had a trading volume of 294,372 shares, compared to its average volume of 520,624. Vericel Co. has a 12-month low of $30.18 and a 12-month high of $53.05. The business has a 50-day moving average price of $47.37 and a two-hundred day moving average price of $41.86. The stock has a market cap of $2.36 billion, a PE ratio of -4,849.15 and a beta of 1.74.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. Vericel had a return on equity of 0.21% and a net margin of 0.22%. The business had revenue of $51.28 million for the quarter, compared to the consensus estimate of $49.07 million. During the same quarter in the prior year, the business earned ($0.16) earnings per share. Vericel's revenue for the quarter was up 25.0% on a year-over-year basis. On average, research analysts anticipate that Vericel Co. will post 0.1 earnings per share for the current year.

Insider Transactions at Vericel

In related news, CEO Dominick Colangelo sold 17,500 shares of the business's stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $44.59, for a total value of $780,325.00. Following the sale, the chief executive officer now directly owns 195,307 shares in the company, valued at approximately $8,708,739.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Vericel news, Director Robert L. Md Zerbe sold 3,278 shares of the stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $51.57, for a total transaction of $169,046.46. Following the sale, the director now owns 23,395 shares in the company, valued at $1,206,480.15. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Dominick Colangelo sold 17,500 shares of the firm's stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $44.59, for a total value of $780,325.00. Following the completion of the transaction, the chief executive officer now directly owns 195,307 shares of the company's stock, valued at $8,708,739.13. The disclosure for this sale can be found here. In the last 90 days, insiders sold 54,267 shares of company stock worth $2,450,996. 7.20% of the stock is owned by company insiders.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.